指南与共识胸部肿瘤放疗放疗物理与技术

FIL专家共识:纵隔霍奇金淋巴瘤的调强与图像引导放疗

Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum.
指南 / 共识 · Radiat Oncol · 2020-03-12

意大利淋巴瘤基金会(FIL)放疗委员会于2018年成立工作组,基于文献回顾与专家讨论制定共识,分析纵隔霍奇金淋巴瘤(HL)中调强放疗(IMRT)与图像引导放疗(IGRT)的应用。共识指出IMRT可降低胸部危及器官高剂量区,但肺和乳腺低剂量可能略高于三维适形放疗,并提出心脏、乳腺、肺和甲状腺的剂量目标,建议个体化选择IGRT。

要点

  • IMRT可显著降低纵隔HL患者胸部危及器官的高剂量区域。
  • 肺和乳腺的低剂量成分在IMRT下可能略高于3D-CRT,取决于技术。
  • 共识提出心脏、乳腺、肺和甲状腺的剂量目标,推荐个体化比较计划。

核心结论

  • 放射肿瘤科医生应充分利用IMRT和IGRT等工具,以最小化危及器官剂量并优化纵隔HL的治疗计划。

研究设计与样本

  • FIL放疗委员会于2018年5月成立工作组,通过会议讨论和文献分享制定专家共识。

主要发现

  • IMRT可能减少所有胸部危及器官的高剂量区域。
  • 肺和乳腺的低剂量成分在IMRT下略高于3D-CRT,取决于技术。
  • 少数研究包含肺和乳腺的特定剂量约束。

关键数值与推荐

  • 共识提出心脏、乳腺、肺和甲状腺的剂量目标。
  • 建议使用IGRT以减少 margins,但无特定指征如呼吸控制技术。
  • 推荐每个患者采用个体化方法,包括比较计划和考虑晚期并发症风险因素。

临床怎么用

  • 在纵隔HL放疗中,可考虑使用IMRT降低危及器官高剂量。
  • 应关注肺和乳腺的低剂量,个体化比较IMRT与3D-CRT计划。
  • IGRT可用于 margin 减少,但需根据患者具体情况决定。

局限性

  • 共识基于专家意见和有限文献,缺乏大规模研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Advances in therapy have resulted in improved cure rates and an increasing number of long-term Hodgkin's lymphoma (HL) survivors. However, radiotherapy (RT)-related late effects are still a significant issue, particularly for younger patients with mediastinal disease (secondary cancers, heart diseases). In many Centers, technological evolution has substantially changed RT planning and delivery. This consensus document aims to analyze the current knowledge of Intensity-Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT) for mediastinal HL and formulate practical recommendations based on scientific evidence and expert opinions. METHODS: A dedicated working group was set up within the Fondazione Italiana Linfomi (FIL) Radiotherapy Committee in May 2018. After a first meeting, the group adopted a dedicated platform to share retrieved articles and other material. Two group coordinators redacted a first document draft, that was further discussed and finalized in two subsequent meetings. Topics of interest were: 1) Published data comparing 3D-conformal radiotherapy (3D-CRT) and IMRT 2) dose objectives for the organs at risk 3) IGRT protocols and motion management. RESULTS: Data review showed that IMRT might allow for an essential reduction in the high-dose regions for all different thoracic OAR. As very few studies included specific dose constraints for lungs and breasts, the low-dose component for these OAR resulted slightly higher with IMRT vs. 3D-CRT, depending on the technique used. We propose a set of dose objectives for the heart, breasts, lungs, and thyroid. The use of IGRT is advised for margin reduction without specific indications, such as the use of breath-holding techniques. An individual approach, including comparative planning and considering different risk factors for late morbidity, is recommended for each patient. CONCLUSIONS: As HL therapy continues to evolve, with an emphasis on treatment reduction, radiation oncologists should use at best all the available tools to minimize the dose to organs at risk and optimize treatment plans. This document provides indications on the use of IMRT/IGRT based on expert consensus, providing a basis for clinical implementation and future development.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Filippi AR, Meregalli S, DI Russo A, et al. Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin's lymphoma involving the mediastinum. Radiat Oncol. 2020. PMID: 32164700. doi:10.1186/s13014-020-01504-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。